Sakamako Mai Kyau Na Maganin CAR-T Da Aka Yi Niyya Ga CD7 Don T-ALL Da T-LBL

Wani gwaji na asibiti da aka yi kwanan nan ya nuna ci gaba mai mahimmanci a fannin maganin cutar sankarar jini ta T-cell mai saurin kamuwa da cutar sankarar jini ta T-cell (T-ALL) da kuma cutar sankarar lymphoblastic ta T-cell (T-LBL) ta amfani da maganin ƙwayoyin T na CD7 da aka yi niyya ga masu karɓar maganin antigen (CAR). Binciken, wanda wata ƙungiya daga Asibitin Hebei Yanda Lu Daopei da Cibiyar Nazarin Hematology ta Lu Daopei suka gudanar, ya shafi marasa lafiya 60 waɗanda suka karɓi allurar ƙwayoyin T na CAR (NS7CAR) da aka zaɓa ta halitta.

Sakamakon gwajin yana da matuƙar ƙarfafa gwiwa. A rana ta 28, kashi 94.4% na marasa lafiya sun sami sassaucin jijiyoyi (CR) a cikin ƙashi. Bugu da ƙari, daga cikin marasa lafiya 32 da ke fama da cutar extramedullary, kashi 78.1% sun nuna sakamako mai kyau, inda kashi 56.3% suka sami sassaucin jijiyoyi gaba ɗaya da kashi 21.9% suka sami sassaucin jijiyoyi na ɗan lokaci. Jimlar rayuwa ta shekaru biyu da ba ta da ci gaba sun kai kashi 63.5% da 53.7%, bi da bi.

Wannan sabuwar hanyar magani abin lura ne saboda yanayin lafiyarsa, inda cutar sakin cytokine ke faruwa a cikin kashi 91.7% na marasa lafiya (galibi a matakin 1/2), kuma an lura da gubar jijiyoyi a cikin kashi 5% na lokuta. Bugu da ƙari, binciken ya gano cewa marasa lafiya da suka ci gaba da yin dashen haɗin gwiwa bayan sun sami CR suna da ƙimar rayuwa mafi girma ba tare da ci gaba ba idan aka kwatanta da waɗanda ba su yi ba.

Kamfaninmu yana kuma binciken yuwuwar maganin ƙwayoyin CD7 CAR-T tare da samfurinmu na musamman, da nufin bayar da gudummawa ga ci gaban magungunan cutar ƙwayoyin T.

Waɗannan binciken sun nuna yuwuwar maganin ƙwayoyin CAR-T da aka yi niyya ga CD7 don samar da sabuwar fata ga marasa lafiya da ke fama da T-ALL da T-LBL masu rashin ƙarfi ko kuma waɗanda suka sake kamuwa da cutar, wanda hakan ke nuna wani muhimmin ci gaba a yaƙin da ake yi da waɗannan cututtuka masu ƙalubale.